Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

December 4, 2026

Study Completion Date

December 4, 2026

Conditions

Recurrent Ovarian CancerRecurrent Uterine CancerMetastatic CancerAdvanced Cancer

Interventions

DRUG

RP-6306

RP-6306 is a selective inhibitor of PKMYT1 kinase. RP-6306 is an investigational agent.

DRUG

Carboplatin

Carboplatin is an antineoplastic agent.

DRUG

Paclitaxel

Paclitaxel is an antineoplastic agent.

Trial Locations (1)

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors

lead

University Health Network, Toronto

OTHER

NCT06107868 - Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer | Biotech Hunter | Biotech Hunter